1. A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Issue 6 (17th February 2017) Authors: Burmester, Gerd R; McInnes, Iain B; Kremer, Joel; Miranda, Pedro; Korkosz, Mariusz; Vencovsky, Jiri; Rubbert-Roth, Andrea; Mysler, Eduardo; Sleeman, Matthew A; Godwood, Alex; Sinibaldi, Dominic; Guo, Xiang; White, Wendy I; Wang, Bing; Wu, Chi-Yuan; Ryan, Patricia C; Close, David; Weinblatt, Micha... Journal: Annals of the rheumatic diseases Issue: Volume 76:Issue 6(2017) Page Start: 1020 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis. (23rd October 2017) Authors: Guo, Xiang; Higgs, Brandon W; Bay-Jensen, Anne-Christine; Wu, Yuling; Karsdal, Morten A; Kuziora, Michael; Godwood, Alex; Close, David; Ryan, Patricia C; Roskos, Lorin K; White, Wendy I Journal: Rheumatology Issue: Volume 57:Number 1(2018) Page Start: 175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗